van Besouw N M, van der Mast B J, de Kuiper P, Smak regoor P J H, Vaessen Lenard M B, Ijzermans J N M, van Gelder T, Weimar W
Department of Internal Medicine, University Hospital Rotterdam-Dijkzigt, The Netherlands.
Clin Exp Immunol. 2002 May;128(2):388-93. doi: 10.1046/j.1365-2249.2002.01810.x.
Stable cadaveric renal transplant patients were routinely converted from cyclosporin A (CsA) to either azathioprine (AZA) or mycophenolate mofetil (MMF) 1 year after transplantation to reduce the side effects of long-term immunosuppressive therapy. Thereafter, the AZA and MMF dose was gradually tapered to 50% at 2 years after transplantation. We questioned whether a reduction of immunosuppressive treatment results in a rise of donor-specific T-cell reactivity. Before transplantation (no immunosuppression), 1 year (high dose immunosuppression) and 2 years (low dose immunosuppression) after transplantation, the T-cell reactivity of peripheral blood mononuclear cells (PBMC) against donor and third-party spleen cells was tested in mixed lymphocyte cultures (MLC) and against tetanus toxoid (TET) to test the general immune response. We also measured the frequency of donor and third-party reactive helper (HTLpf) and cytotoxic (CTLpf) T-lymphocyte precursors in a limiting dilution assay. Donor-specific responses, calculated by relative responses (RR = donor/third-party reactivity), were determined. Comparing responses after transplantation during high dose immunosuppression with responses before transplantation (no immmunosuppression), the donor-specific MLC-RR (P = 0.04), HTLp-RR (P = 0.04) and CTLp-RR (P = 0.09) decreased, while the TET-reactivity did not change. Comparing the responses during low dose with high dose immunosuppression, no donor- specific differences were found in the MLC-RR, HTLp-RR and CTLp-RR, although TET-reactivity increased considerably (P = 0.0005). We observed a reduction in donor-specific T-cell reactivity in stable patients after renal transplantation during in vivo high dose immunosuppression. Tapering of the immunosuppressive load had no rebound effect on the donor-specific reactivity, while it allowed recovery of the response to nominal antigens.
稳定的尸体肾移植患者在移植后1年常规从环孢素A(CsA)转换为硫唑嘌呤(AZA)或霉酚酸酯(MMF),以减少长期免疫抑制治疗的副作用。此后,AZA和MMF剂量在移植后2年逐渐减至50%。我们质疑免疫抑制治疗的减少是否会导致供体特异性T细胞反应性升高。在移植前(无免疫抑制)、移植后1年(高剂量免疫抑制)和2年(低剂量免疫抑制),在混合淋巴细胞培养(MLC)中检测外周血单个核细胞(PBMC)对供体和第三方脾细胞的T细胞反应性,并检测对破伤风类毒素(TET)的反应以测试总体免疫反应。我们还在有限稀释试验中测量了供体和第三方反应性辅助性(HTLpf)和细胞毒性(CTLpf)T淋巴细胞前体的频率。通过相对反应(RR = 供体/第三方反应性)计算供体特异性反应。将高剂量免疫抑制期间移植后的反应与移植前(无免疫抑制)的反应进行比较,供体特异性MLC-RR(P = 0.04)、HTLp-RR(P = 0.04)和CTLp-RR(P = 0.09)降低,而TET反应性未改变。将低剂量与高剂量免疫抑制期间的反应进行比较,在MLC-RR、HTLp-RR和CTLp-RR中未发现供体特异性差异,尽管TET反应性显著增加(P = 0.0005)。我们观察到肾移植后稳定患者在体内高剂量免疫抑制期间供体特异性T细胞反应性降低。免疫抑制负荷的逐渐减少对供体特异性反应性没有反弹作用,同时它允许对名义抗原的反应恢复。